Pacific Biosciences of California (NASDAQ:PACB) shares are on a 42% nosedive after announcing this morning before market open that Roche has terminated its collaboration …
Cantor analyst Bryan Brokmeier reiterated a Buy rating on shares of Cerus Corporation (NASDAQ:CERS), with a $9.00 price target, after the FDA announced that it is requesting that …
Following market close yesterday, Illumina, Inc. (NASDAQ:ILMN) reported second quarter revenue results of $600.
In a research report sent to investors Thursday, Cantor analyst Bryan Brokmeier assumed coverage on shares of Cerus Corporation (NASDAQ:CERS), with a Buy rating and price …
In a research report published yesterday, Cantor analyst Bryan Brokmeier initiated coverage on shares of TrovaGene Inc (NASDAQ:TROV) with a Buy rating and price …
In a research report released yesterday, Cantor analyst Bryan Brokmeier initiated coverage on shares of Illumina, Inc. (NASDAQ:ILMN) with a Buy rating and a …